Skip to main content

Table 2 Subgroup analysis of blood-based PD-L1 markers and OS/PFS in NSCLC receiving ICIs

From: Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis

Subgroup

N

HR (95% CI)

Interaction

Heterogeneity

OS

  

P

I2%, P

P interaction

sPD-L1

 Total

9

2.11 (1.59–2.80)

 < 0.001

0%, 0.677

 

Time point

    

0.295

 Pre-treatment

6

2.32 (1.68–3.18)

 < 0.001

0%, 0.983

 

 Post-treatment

3

1.46 (0.65–3.26)

0.360

43.3%, 0.171

 

Sample size

    

0.631

  > 100

2

2.36 (1.37–4.07)

 < 0.01

0%, 0.514

 

  ≤ 100

7

2.02 (1.46–2.81)

 < 0.001

0%, 0.533

 

Region

    

0.890

 Asia

2

2.05 (1.24–3.40)

 < 0.01

0%, 0.970

 

 Europe

7

2.14 (1.52–3.00)

 < 0.001

0%, 0.456

 

PD-L1 in CTCs

 Total

6

0.75 (0.49–1.13)

0.170

33.5%, 0.185

 

Time point

    

0.802

 Pre-treatment

5

0.73 (0.44–1.21)

0.222

46.3%, 0.114

 

 Post-treatment

1

0.83 (0.35–1.98)

0.674

-

 

 Sample size

    

0.156

  > 30

5

0.84 (0.54–1.30)

0.426

25.2%, 0.254

 

  ≤ 30

1

0.43 (0.19–0.97)

 < 0.05

-

 

Region

    

0.415

 Asia

2

0.59 (0.31–1.12)

0.104

14.6%, 0.279

 

 Europe

4

0.84 (0.48–1.46)

0.529

43.9%, 0.148

 

PFS

 sPD-L1

  Total

7

2.14 (1.59–2.88)

 < 0.001

0%, 0.443

 

 Time point

    

0.250

  Pre-treatment

4

2.52 (1.72–3.68)

 < 0.001

0%, 0.730

 

  Post-treatment

3

1.62 (0.92–2.86)

0.097

27.9%, 0.250

 

 Sample size

    

0.562

   > 100

2

2.47 (1.37–4.44)

 < 0.01

19.8%, 0.264

 

   ≤ 100

5

2.01 (1.38–2.91)

 < 0.001

5.5%, 0.375

 

 Region

    

0.726

  Asia

1

1.91 (0.97–3.75)

0.061

-

 

  Europe

6

2.19 (1.53–3.12)

 < 0.001

12.1%, 0.338

 

 PD-L1 in CTCs

  Total

8

0.79 (0.59–1.06)

0.12

20.6%, 0.266

 

 Time point

    

0.530

  Pre-treatment

6

0.75 (0.52–1.08)

0.124

36.8%, 0.161

 

  Post-treatment

2

0.95 (0.50–1.80)

0.882

0%, 0.449

 

 Sample size

    

0.754

   > 30

5

0.82 (0.57–1.17)

0.267

30.0%, 0.222

 

   ≤ 30

3

0.73 (0.39–1.38)

0.332

30.6%, 0.237

 

 Region

    

0.924

  Asia

3

0.71 (0.39–1.27)

0.248

29.1%, 0.244

 

  Europe

4

0.82 (0.53–1.26)

0.368

46.5%, 0.132

 

  America

1

0.83 (0.24–2.86)

0.768

-

 
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us